Neurophysiological biomarkers for schizophrenia therapeutics

Biomarkers in Neuropsychiatry

Juan L. Molina¹  Yash B. Joshi²  John A. Nungaray²  Michael L. Thomas³  Gregory A. Light³  Juliana E. Kotz³  Neal R. Swerdlow³  Savita G. Bhakta³  Lauren Cardoso³ 

[1] Corresponding author at: UCSD Department of Psychiatry, 9500 Gilman Dr., La Jolla, CA, 92093-0804, United States.;VA Desert Pacific Mental Illness Research, Education and Clinical Center (MIRECC), VA San Diego Healthcare System, San Diego, CA, United States;Department of Psychiatry, 0804, University of California, San Diego, La Jolla, CA, 92093, United States;

关键词: Auditory discrimination;    Biomarker;    Electroencephalography;    Neurocognition;    Schizophrenia;   

DOI  :  

来源: DOAJ

【 摘 要 】

Chronic psychotic disorders, including schizophrenia (SZ), are highly heterogeneous at many levels of analysis, from genetics to clinical presentation and treatment sensitivity. This heterogeneity reflects both a divergence of shared biological pathways moving from over a hundred “risk genes” to many different clinical phenotypes, and the convergence of distinct biological pathways to a shared “phenocopies” of chronic psychosis. Successful strategies for developing “next generation” interventions in SZ – including “pro-cognitive” medications, cognitive remediation, neurostimulation and combinations thereof – will address these pathways to clinical heterogeneity by using biological signals, or “biomarkers” that characterize treatment-sensitive subpopulations. Identifying and detecting these meaningful signals in the complex biology of SZ is a vexing scientific challenge. We propose that rational starting points are neurophysiological measures of early auditory information processing (EAIP), based on their functional importance as strong mediators of both cognition and function in SZ, their plasticity in response to both pharmacologic and non-pharmacologic therapeutic “challenge”, and their experimental characteristics as highly quantitative, robust and reliable measures of brain activity. Here we describe some of our current approaches to developing neurophysiological biomarkers for “next generation” therapeutic sensitivity in SZ, and some potentially novel experimental strategies that we envision on the near horizon.

【 授权许可】

Unknown